SABS

NASDAQStock

SAB Biotherapeutics, Inc.

$4.13-0.47 (-10.13%)

52-Week Range

$1.11

$4.59

Key Stats

Market Cap

—

P/E Ratio

—

Dividend Yield

—

Beta

0.61

Volume

495.9K

Avg Volume

713.3K

Performance

+11.41%

+14.75%

+118.57%

YTD

+21.75%

+185.09%

-10.00%

-93.71%

Price Chart

ETF Exposure

SABS is held by 9 ETFs

ETF	Fund Name	Weight	Shares	Market Value	Fund AUM	Expense Ratio
SURI	Simplify Propel Opportunities ETF	1.28%	208,227	$956K	$76.9M	2.82%
AVSC	Avantis U.S. Small Cap Equity ETF	0.01%	32,191	$148K	$2.36B	0.25%
VCNS.TO	Vanguard Conservative ETF Portfolio	0.00%	80	$480	$820.6M	0.25%
VEQT.TO	Vanguard All-Equity ETF Portfolio	0.00%	2,882	$17K	$12.17B	0.24%
VRIF.TO	Vanguard Retirement Income ETF Portfolio	0.00%	13	$82	$337.7M	0.32%
VTI	Vanguard Total Stock Market ETF	0.00%	1,640,793	$7.2M	$2.10T	0.03%
VUN.TO	Vanguard U.S. Total Market Index ETF	0.00%	8,630	$51K	$15.33B	0.17%
VUS.TO	Vanguard U.S. Total Market Index ETF (CAD-hedged)	0.00%	744	$4K	$1.29B	0.17%
VXF	Vanguard Extended Market ETF	0.00%	76,487	$336K	$84.10B	0.05%

About SABS ETF Exposure

SAB Biotherapeutics, Inc. (SABS) is held by 9 exchange-traded funds, making it one of the stocks with significant ETF exposure. The stock currently trades at $4.13. Investors can gain exposure to SABS through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold SABS, sorted by portfolio weight.